New triple combo aims to break through treatment barriers for advanced colorectal cancer
Disease control
Recruiting now
This early-phase trial tests a combination of immune cells (DC-CIK), a bispecific antibody, and a targeted drug as a third-line treatment for advanced colorectal cancer. It enrolls 14 adults who have failed standard therapies. The goal is to see if this triple therapy can shrink …
Phase: EARLY_PHASE1 • Sponsor: JIANG LONGWEI • Aim: Disease control
Last updated May 26, 2026 09:59 UTC